Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Down 56.6% in March

Aprea Therapeutics, Inc. (NASDAQ:APRE) saw a large decline in short interest in the month of March. As of March 13th, there was short interest totaling 106,655 shares, a decline of 56.6% from the February 26th total of 245,983 shares. Currently, 1.1% of the company’s shares are short sold. Based on an average daily volume of 105,670 shares, the days-to-cover ratio is presently 1.0 days.

Analyst Ratings Changes

Several equities research analysts recently commented on APRE shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aprea Therapeutics in a research note on Wednesday, January 21st. HC Wainwright restated a “buy” rating and set a $4.00 price target (down from $5.00) on shares of Aprea Therapeutics in a report on Thursday, January 29th. Zacks Research raised shares of Aprea Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, February 16th. Finally, Wedbush lowered their price objective on shares of Aprea Therapeutics from $11.00 to $7.00 and set an “outperform” rating for the company in a research note on Tuesday, February 10th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Aprea Therapeutics currently has a consensus rating of “Hold” and an average price target of $5.50.

Aprea Therapeutics Price Performance

APRE stock opened at $0.68 on Friday. The company’s 50-day moving average is $0.76 and its 200-day moving average is $1.07. The stock has a market capitalization of $7.82 million, a PE ratio of -0.34 and a beta of 1.42. Aprea Therapeutics has a 1 year low of $0.55 and a 1 year high of $2.30.

Aprea Therapeutics (NASDAQ:APRE) last posted its quarterly earnings results on Monday, March 16th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.06. The business had revenue of $0.00 million for the quarter. Aprea Therapeutics had a negative return on equity of 96.33% and a negative net margin of 4,405.59%. On average, analysts anticipate that Aprea Therapeutics will post -2.55 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aprea Therapeutics

An institutional investor recently bought a new position in Aprea Therapeutics stock. DRW Securities LLC purchased a new stake in Aprea Therapeutics, Inc. (NASDAQ:APRE) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 120,651 shares of the company’s stock, valued at approximately $103,000. DRW Securities LLC owned 1.73% of Aprea Therapeutics at the end of the most recent quarter. 34.19% of the stock is currently owned by hedge funds and other institutional investors.

About Aprea Therapeutics

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.